相关临床试验
6
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
83.3%
已完成
1
16.7%
暂无批准数据
- Researchers identified a distinct subgroup of highly functional CAR T cells whose abundance correlates directly with the success of low-dose CAR T-cell therapy. - The absolute number of these specific cells could serve as a future biomarker for predicting treatment response, even when overall cell counts are low. - The state of a patient's immune system before cell manufacturing begins also influences whether effective CAR T-cell products can be generated. - Findings, published in Nature Communications, could further personalize cancer immunotherapy and help conserve costly healthcare resources.
- A 17-year-old patient with advanced metastatic nephroblastoma achieved deep remission following treatment with Immatics' PRAME-directed TCR T-cell therapy at KiTZ in Heidelberg. - The patient had rapidly progressing disease with brain, liver, and lung metastases and had exhausted all available treatment options before receiving the experimental therapy. - PET scan and MRI imaging demonstrated marked tumor regression across all lesion sites, with molecular remission confirmed by liquid biopsy showing no tumor-derived DNA. - The response remained ongoing at six months of follow-up, with the patient in excellent physical condition despite manageable cytokine release syndrome during treatment.
- International researchers identified bemnifosbuvir, a nucleotide analogue already in hepatitis C clinical trials, as an effective compound against hepatitis E virus replication in laboratory studies. - The drug successfully prevented hepatitis E virus replication in cell cultures while maintaining cell viability, and animal studies confirmed its efficacy in reducing viral activity and liver inflammation. - With hepatitis E causing approximately 70,000 deaths annually and no approved vaccines or treatments available, bemnifosbuvir could potentially be repurposed for off-label use if hepatitis C trials succeed. - The research represents a collaborative effort between institutions in Germany and China, offering hope for addressing a significant global health burden affecting millions worldwide.
- OncoHost published a landmark study in JPBA introducing a validated computational framework that harmonizes serum and plasma proteomic datasets, overcoming a long-standing analytical barrier in biomarker research. - The multi-institutional study analyzed 7,289 proteins across 177 matched serum-plasma sample pairs from cancer patients, finding 91.6% of proteins showed statistically significant correlation (p < 0.05) between specimen types. - The bridging methodology was successfully validated using OncoHost's PROphet® AI platform for non-small cell lung cancer immunotherapy prediction, maintaining predictive accuracy when applied to transformed serum data. - This breakthrough enables researchers to combine previously siloed datasets, accelerating biomarker discovery and validation while enhancing clinical sample flexibility in precision oncology applications.
- SOFIE Biosciences has dosed the first patient in its FAPI-GO Phase 3 trial evaluating [18F]FAPI-74 PET/CT for detecting metastatic disease in gastroesophageal cancers, marking a significant milestone in FAPI-based diagnostics. - The company launched a second Phase 3 study, FAPI-PRO, in December 2025 to assess [18F]FAPI-74's clinical utility in pancreatic ductal adenocarcinoma patients. - Previous Phase 2 results demonstrated promising efficacy with [18F]FAPI-74 showing 100% positive predictive value for detecting FAP-expressing cells and 94% positive predictive value for GI malignancies. - Both multi-site trials target the Fibroblast Activation Protein (FAP) in cancer-associated fibroblasts, representing a novel approach to cancer imaging through the tumor microenvironment.
- Johnson & Johnson's Phase 2 MajesTEC-5 study demonstrates that 100% of evaluable patients achieved minimal residual disease negativity following TECVAYLI and DARZALEX FASPRO-based induction therapy. - The investigational immune-based regimen achieved 100% overall response rates and 85.7% complete response rates in 49 transplant-eligible patients with newly diagnosed multiple myeloma. - Safety analysis showed manageable tolerability with no treatment discontinuations, no Grade 5 adverse events, and no cases of immune effector cell-associated neurotoxicity syndrome.
- A European consortium led by OncoHost has been awarded €2.5 million from the EIC Transition Programme to develop NeutroFlow, a diagnostic test predicting patient response to immune checkpoint inhibitors across five cancer types. - The point-of-care test leverages breakthrough research on Ly6Ehi neutrophils as predictive biomarkers and will use flow cytometry technology deployable in standard hospital settings. - The collaborative project involves prestigious institutions including Heidelberg University Hospital, European Institute of Oncology, and Virgen Macarena University Hospital, with activities launching in May 2025.
- A second-generation BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma and AL amyloidosis, achieving a 5/6 overall response rate with 4 complete responses. - The novel therapy showed a favorable safety profile with manageable toxicity, including low incidence of severe cytokine release syndrome and no neurotoxicity, even in patients with significant organ dysfunction. - These promising results have prompted further investigation through ongoing clinical trials, including CARLOTTA001 (NCT05836896) and the CLEAR AL trial, potentially offering new hope for difficult-to-treat hematologic malignancies.
- Adjuvant gemcitabine-capecitabine (GemCap) demonstrates prolonged overall survival compared to gemcitabine alone in pancreatic adenocarcinoma patients. - Median overall survival was 31.6 months with GemCap versus 28.4 months with gemcitabine monotherapy (HR=0.83, P=0.031). - In patients with R0 resection, GemCap significantly improved median overall survival to 49.9 months compared to 32.2 months with gemcitabine (HR=0.63, P=0.002). - GemCap may be particularly effective in patients with R0 resection and lymph node-negative disease, suggesting its utility in specific patient subgroups.
